CD-30 Immunohistochemistry at Lahore PCR Lab

CD-30 Immunohistochemistry at Lahore PCR Lab

CD-30 Immunohistochemistry (IHC) is a highly specialized, state-of-the-art pathology investigation performed to detect the expression of the CD30 antigen (also known as Ki-1 antigen) in tissue specimens. At Lahore PCR Lab in Lahore, Pakistan, this diagnostic test is executed using advanced automated staining platforms and high-affinity monoclonal antibodies (typically the Ber-H2 clone) to ensure maximum sensitivity, specificity, and reproducibility. The CD30 antigen is a 120 kDa transmembrane glycoprotein belonging to the tumor necrosis factor receptor (TNFR) superfamily. While its expression is physiologically restricted to a small population of activated T and B lymphocytes in healthy lymphoid tissues, its pathological upregulation is a hallmark of several hematologic malignancies and specific non-lymphoid tumors.

The clinical value of CD-30 Immunohistochemistry at Lahore PCR Lab lies in its exceptional utility for differential diagnosis within hematopathology. It serves as the diagnostic gold standard for identifying classic Hodgkin Lymphoma (cHL) and Anaplastic Large Cell Lymphoma (ALCL). Furthermore, CD30 expression profiling has transitioned from a purely diagnostic tool to a critical predictive biomarker. With the advent of targeted antibody-drug conjugates, such as brentuximab vedotin, identifying CD30 positivity is essential for guiding therapeutic decisions in patients with refractory lymphomas. By analyzing the precise cellular localization, staining intensity, and percentage of positive cells, our consultant pathologists provide clinicians with the definitive diagnostic insights necessary to formulate highly personalized oncology treatment protocols.

Clinical Procedure: What to Expect

Patient Preparation

Because CD-30 Immunohistochemistry is performed on tissue specimens rather than directly on the patient, preparation primarily revolves around the proper collection, preservation, and submission of the biopsy material. Patients and referring physicians should observe the following guidelines:

• Tissue Submission: Submit the Formalin-Fixed Paraffin-Embedded (FFPE) tissue block (commonly referred to as the “biopsy block”) along with the corresponding Hematoxylin and Eosin (H&E) stained slides.
• Clinical History: Provide a complete clinical history, including previous pathology reports, radiological findings, suspected clinical diagnoses, and details of any prior chemotherapy or radiotherapy.
• Fixation Requirements: Ensure the tissue was fixed in 10% neutral buffered formalin within 30 minutes of surgical excision. Optimal fixation (typically 6 to 72 hours) is critical to prevent antigen degradation and avoid false-negative results.
• No Direct Patient Fasting: No fasting or specific physical preparation is required for the patient unless they are undergoing the primary biopsy procedure on the same day.

During the Procedure

Once the specimen is received at the histopathology division of Lahore PCR Lab, it undergoes a rigorous, multi-step laboratory process conducted by trained histotechnicians and evaluated by consultant pathologists:

• Microtomy: The paraffin block is sectioned using a precision microtome to obtain ultra-thin sections of approximately 3 to 4 micrometers. These sections are floated onto charged glass slides to prevent tissue detachment during subsequent processing.
• Deparaffinization and Rehydration: The slides are heated and treated with xylene to remove the paraffin wax, followed by graded alcohols to rehydrate the tissue sections.
• Antigen Retrieval: To uncover the CD30 epitopes masked during formalin fixation, Heat-Induced Epitope Retrieval (HIER) is performed using specialized buffer solutions (such as EDTA or citrate buffer) under controlled temperature and pressure.
• Primary Antibody Incubation: The tissue sections are incubated with a highly specific primary monoclonal antibody directed against the CD30 antigen.
• Detection System: A polymer-based secondary detection system conjugated with horseradish peroxidase (HRP) is applied, followed by the addition of 3,3’-Diaminobenzidine (DAB) chromogen. This reaction produces a highly visible, insoluble brown precipitate at the site of antigen-antibody binding.
• Counterstaining and Mounting: The slides are counterstained with hematoxylin to visualize cellular nuclei, dehydrated through graded alcohols, cleared in xylene, and sealed with a coverslip using a permanent mounting medium.
• Microscopic Evaluation: A consultant pathologist examines the slides under a high-resolution light microscope to evaluate the staining pattern, intensity, and distribution.

When is a CD-30 Immunohistochemistry Performed?

Suspected Classic Hodgkin Lymphoma

Physicians request CD-30 IHC when a patient presents with persistent lymphadenopathy, night sweats, unexplained weight loss, and fever (B symptoms), and the initial H&E stain reveals atypical, multinucleated giant cells resembling Reed-Sternberg (RS) cells. CD30 is strongly and diffusely positive in virtually all cases of classic Hodgkin Lymphoma, showing a characteristic membranous and paranuclear/Golgi zone staining pattern. This test is crucial to differentiate cHL from nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), which is typically CD30 negative, and from reactive lymphadenitis.

Anaplastic Large Cell Lymphoma (ALCL) Diagnosis

In patients presenting with rapidly progressive lymphadenopathy or extranodal masses, pathologists utilize CD-30 IHC to confirm or rule out Anaplastic Large Cell Lymphoma, a highly aggressive T-cell malignancy. ALCL is characterized by a universal, strong, and diffuse expression of CD30 in almost 100% of the neoplastic “hallmark” cells. Performing this test alongside ALK (Anaplastic Lymphoma Kinase) staining allows pathologists to subclassify ALCL into ALK-positive and ALK-negative variants, which carry distinct prognostic implications.

Cutaneous T-Cell Lymphoproliferative Disorders

Dermatologists and oncologists order CD-30 IHC to evaluate suspicious, persistent skin lesions, nodules, or plaques. The test is essential for diagnosing and differentiating primary cutaneous CD30-positive lymphoproliferative disorders, which include Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and Lymphomatoid Papulosis (LyP). It also helps identify large cell transformation in patients with pre-existing Mycosis Fungoides, which is associated with a more aggressive clinical course and requires a shift in therapeutic strategy.

Evaluation of Embryonal Carcinoma

In the diagnostic workup of germ cell tumors, particularly testicular and ovarian neoplasms, CD-30 IHC serves as an invaluable diagnostic marker. Embryonal carcinoma, a highly aggressive germ cell tumor, consistently demonstrates strong, diffuse membranous CD30 expression. Pathologists routinely employ CD30 to distinguish embryonal carcinoma from other germ cell tumors such as seminoma/dysgerminoma, yolk sac tumor, and choriocarcinoma, which are characteristically CD30 negative.

Selection for Targeted Immunotherapy

Oncologists frequently request CD-30 IHC for patients diagnosed with various peripheral T-cell lymphomas (PTCL), diffuse large B-cell lymphomas (DLBCL), or mycosis fungoides to assess their eligibility for targeted therapy. Because brentuximab vedotin specifically targets CD30-expressing cells, demonstrating even focal or low-level CD30 expression via immunohistochemistry can qualify a patient for this highly effective, FDA-approved antibody-drug conjugate therapy, offering hope in refractory cases.

What Does a CD-30 Immunohistochemistry Detect?

CD-30 Immunohistochemistry is designed to detect the presence, localization, intensity, and distribution of the CD30 glycoprotein within a tissue sample. Specifically, the test evaluates and detects:

• Membranous Staining: A continuous or discontinuous brown staining along the cytoplasmic membrane of neoplastic cells.
• Paranuclear/Golgi Dot-like Staining: A highly characteristic, localized brown dot within the cytoplasm adjacent to the nucleus, representing antigen accumulation in the Golgi apparatus.
• Classic Reed-Sternberg Cells: Large, binucleated or multinucleated cells with prominent eosinophilic nucleoli that show intense CD30 positivity in classic Hodgkin Lymphoma.
• Hodgkin Variants: Mononuclear Hodgkin cells and lacunar cells exhibiting strong CD30 expression.
• Hallmark Cells of ALCL: Large pleomorphic cells with eccentric, kidney- or horseshoe-shaped nuclei showing diffuse and intense CD30 positivity.
• Reactive Immunoblasts: Scattered, small-to-medium-sized activated T and B lymphocytes in reactive lymph nodes showing weak-to-moderate CD30 expression.
• Embryonal Carcinoma Cells: Highly atypical epithelial-like cells in germ cell tumors displaying strong membranous CD30 positivity.
• Lymphomatoid Papulosis Cells: Atypical CD30-positive cells infiltrating the dermis in a background of mixed inflammatory cells.
• Large Cell Transformation in Mycosis Fungoides: An increase in CD30-positive large cells (comprising more than 25% of the infiltrate) within cutaneous lesions.
• Staining Intensity: Categorization of antigen expression as weak (1+), moderate (2+), or strong (3+).
• Percentage of Positive Tumor Cells: Quantification of the tumor load expressing the CD30 antigen (e.g., >10%, >50%, or diffuse >80%).
• Absence of Staining in Seminomas: Confirming a diagnosis of seminoma by demonstrating a lack of CD30 expression.
• Absence of Staining in NLPHL: Helping rule out classic Hodgkin Lymphoma by confirming that the atypical L&H (popcorn) cells are CD30 negative.
• Co-expression Patterns: Assisting in multi-marker IHC panels to correlate CD30 positivity with other markers like CD15, CD45, ALK, and PAX5.

Turnaround Time and Report Access at Lahore PCR Lab

At Lahore PCR Lab, we understand that a timely and accurate diagnosis is critical for initiating life-saving oncological treatments. The turnaround time (TAT) for CD-30 Immunohistochemistry is typically 3 to 5 working days. This timeframe ensures that the tissue undergoes meticulous processing, optimal antigen retrieval, precise staining, and a comprehensive double-reporting protocol by our senior consultant pathologists. Once the report is finalized, patients and referring clinicians receive an automated SMS notification. Reports can be securely accessed and downloaded online via the Lahore PCR Lab official patient portal, or collected in person from our main diagnostic center in Lahore.

CD-30 Immunohistochemistry Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Reed-Sternberg Cells	Absent	Strong membranous and Golgi CD30 positivity (Classic Hodgkin Lymphoma)
Anaplastic Large Cells	Absent	Strong, diffuse, uniform CD30 positivity (Anaplastic Large Cell Lymphoma)
Reactive Lymph Node Immunoblasts	Occasional, scattered, weakly positive cells	Increased number of CD30+ immunoblasts (Viral infections, e.g., EBV/Infectious Mononucleosis)
Germ Cell Tumors (Embryonal Carcinoma)	Negative	Strong, diffuse membranous CD30 expression
Germ Cell Tumors (Seminoma)	Negative	Consistently negative (helps rule out embryonal carcinoma)
Cutaneous Lymphoid Infiltrates	Absent or rare reactive cells	Dense sheets of CD30+ atypical T-cells (pcALCL, Lymphomatoid Papulosis)
B-cell Lymphomas (DLBCL)	Typically negative	Subset of cases showing variable, focal, or diffuse CD30 positivity

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for CD-30 Immunohistochemistry?

• Experienced Healthcare Professionals: Our histopathology department is led by highly qualified, fellowship-trained consultant pathologists with extensive expertise in hematopathology and oncopathology.
• Patient-Focused Care: We prioritize patient comfort, clear communication, and compassionate support throughout the diagnostic journey.
• Quality Diagnostic Services: Lahore PCR Lab adheres to strict international quality control guidelines, ensuring highly reproducible and clinically reliable IHC staining.
• Professional Reporting: Our reports provide detailed diagnostic descriptions, including staining intensity, percentage of positive cells, and clinical correlation to guide oncologists.
• Modern Diagnostic Approach: We utilize advanced automated staining platforms that minimize human error and optimize antibody-antigen binding.
• Comfortable Environment: Our main collection centers in Lahore offer a clean, professional, and welcoming environment for patients submitting specimens.
• Convenient Location: Situated centrally in Lahore, our laboratory is easily accessible for patients, hospitals, and clinics across the region.
• Commitment to Accurate Diagnosis: We employ rigorous internal and external quality assurance protocols to ensure every CD-30 IHC slide is interpreted with absolute precision.